This panel will discuss the current state of affairs for virus testing including genotyping, antigen testing including limitations, and the value for antibody testing including total, virus neutralization, and surrogate neutralization testing in light of COVID variants. Also cover home testing options and limitations.
Dr. Wu's research involves pharmacogenomics, cardiac biomarkers and clinical toxicology. With the onset of the COVID-19 pandemic, he has switch his focus towards molecular testing for the virus, antigen and antibodies after an infection and after a vaccine. Throughout his career, he has been a leader in promoting the value of clinical laboratory testing to the medical world, but especially the lay public. During the early months of the pandemic, the absence lab testing availability was directly linked to the spread of the virus.
Dr. Pestano is an experienced leader in Product Development and clinical Laboratory Operations. Prior to joining Biodesix, Dr. Pestano held senior positions in Pharma Services, R&D and Project Leadership at Ventana Medical Systems, a member of the Roche Group. Dr. Pestano’s experiences are specialized in high complexity molecular diagnostics for oncology and virology and include molecular, serologic, and proteomic testing. Dr. Pestano is the co-inventor on multiple national and international patents for diagnostic tests. He has also fostered many collaborations in academia, industry, quality, and public health consortia as a part of new product development. Dr. Pestano received his Ph.D. in Molecular Cell Biology at The Graduate Center, City University of New York where his thesis focused on vaccine development for novel genetic variants of HIV-1. He conducted his post-doctoral training in Cancer Immunology and AIDS at the Dana Farber Cancer Institute, Harvard Medical School.
Real World Testing in Support of Back to Work Programs
Panelist providing real world perspective on multiple modalities of covid testing and studies in support of back to work programs.
Internationally recognized expert in the field of influenza viral genomics and diagnostics. Responsible for Manufacturing and Maintaining 6 FDA approved diagnostic assays including CDC’s Influenza A/B SARS-CoV-2 Multiplex Assay. Sequenced and published first RNA genome by sequencing the viral RNA directly. Team is one of the largest producers of influenza genomic data in the world.
Dr Jacobson is a board-certified family physician and HIV/STD specialist. Prior to joining CDPH, Dr Jacobson was the Senior HIV TB Care and Treatment Advisor to the United States’ Center for Disease Control and Prevention (CDC) for the country of Uganda. Dr Jacobson was an Associate Professor of Clinical Family Medicine at the University of Southern California, Keck School of Medicine for over 20 years where she directed 3 medical school courses, was a principal investigator on a number of multisite studies on acute HIV, testing, rapid treatment, and linkage to care, and was the Medical Director of the Los Angeles Region AIDS Education and Training Center. She is also a Medical Officer with the US. Department of Health and Human Services which serves the Midwestern United States to Guam for National Disaster Management. Dr Jacobson has more than 27 years of clinical experience and has trained thousands providers in clinical care.